Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Foghorn Therapeutics Provides Second Quarter 2023 Financial
— Initiating FHD-286 combination study in AML in the third quarter of 2023 — Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND — Cash, cash equivalents, and marketable…